Literature DB >> 27424939

Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.

M Kerkhof1, R E Hagenbeek2, B F W van der Kallen2, G J Lycklama À Nijeholt2, L Dirven3, M J B Taphoorn4,3, M J Vos4.   

Abstract

BACKGROUND AND
PURPOSE: Conventional magnetic resonance imaging (MRI) has limited value for differentiation of true tumor progression and pseudoprogression in treated glioblastoma multiforme (GBM). Perfusion weighted imaging (PWI) may be helpful in the differentiation of these two phenomena. Here interobserver variability in routine radiological evaluation of GBM patients is assessed using MRI, including PWI.
METHODS: Three experienced neuroradiologists evaluated MR scans of 28 GBM patients during temozolomide chemoradiotherapy at three time points: preoperative (MR1) and postoperative (MR2) MR scan and the follow-up MR scan after three cycles of adjuvant temozolomide (MR3). Tumor size was measured both on T1 post-contrast and T2 weighted images according to the Response Assessment in Neuro-Oncology criteria. PW images of MR3 were evaluated by visual inspection of relative cerebral blood volume (rCBV) color maps and by quantitative rCBV measurements of enhancing areas with highest rCBV. Image interpretability of PW images was also scored. Finally, the neuroradiologists gave a conclusion on tumor status, based on the interpretation of both T1 and T2 weighted images (MR1, MR2 and MR3) in combination with PWI (MR3).
RESULTS: Interobserver agreement on visual interpretation of rCBV maps was good (κ = 0.63) but poor on quantitative rCBV measurements and on interpretability of perfusion images (intraclass correlation coefficient 0.37 and κ = 0.23, respectively). Interobserver agreement on the overall conclusion of tumor status was moderate (κ = 0.48).
CONCLUSIONS: Interobserver agreement on the visual interpretation of PWI color maps was good. However, overall interpretation of MR scans (using both conventional and PW images) showed considerable interobserver variability. Therefore, caution should be applied when interpreting MRI results during chemoradiation therapy.
© 2016 EAN.

Entities:  

Keywords:  MR imaging; glioblastoma; interobserver variability; perfusion MRI

Mesh:

Year:  2016        PMID: 27424939     DOI: 10.1111/ene.13070

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state.

Authors:  Tyler C Steed; Jeffrey M Treiber; Birra Taha; H Billur Engin; Hannah Carter; Kunal S Patel; Anders M Dale; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2020-06-15       Impact factor: 4.130

2.  Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  Neuroradiology       Date:  2017-12-07       Impact factor: 2.804

3.  Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry.

Authors:  Thomas Huber; Georgina Alber; Stefanie Bette; Johannes Kaesmacher; Tobias Boeckh-Behrens; Jens Gempt; Florian Ringel; Hanno M Specht; Bernhard Meyer; Claus Zimmer; Benedikt Wiestler; Jan S Kirschke
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

4.  Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.

Authors:  Hassan M Fathallah-Shaykh; Andrew DeAtkine; Elizabeth Coffee; Elias Khayat; Asim K Bag; Xiaosi Han; Paula Province Warren; Markus Bredel; John Fiveash; James Markert; Nidhal Bouaynaya; Louis B Nabors
Journal:  PLoS Med       Date:  2019-05-28       Impact factor: 11.069

5.  Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.

Authors:  Margaux Roques; Isabelle Catalaa; Magali Raveneau; Justine Attal; Aurore Siegfried; Jean Darcourt; Christophe Cognard; Nicolas Menjot de Champfleur; Fabrice Bonneville
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

6.  Clinical applicability of and changes in perfusion MR imaging in brain metastases after stereotactic radiotherapy.

Authors:  M Kerkhof; I Ganeff; R G J Wiggenraad; G J Lycklama À Nijeholt; S Hammer; M J B Taphoorn; L Dirven; M J Vos
Journal:  J Neurooncol       Date:  2018-02-01       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.